Articles By Jack Cush, MD
RheumNow Week in Review – 2 September 2016
Dr. Jack Cush reviews highlights from this week in RheumNow:
Read Article
Flares Portend Damage in Rheumatoid Arthritis - Time for a New Strategy?
Disease flares are common in rheumatoid arthritis (RA), often causing patients to seek additional care, if not medication. The frequency of flares varies amongst studies in different populations. But the consequence of flares has only recently been studied.
Read Article
Cost of Osteoporosis Care in the USA
The 2010 NHANES study suggests that the overall prevalence of osteoporosis (OP) in the USA is ~10% or 10.2 million older adults (> 50 yrs) had osteoporosis.
Read Article
NIH Discovers Otulipenia - New Infantile Autoinflammatory Disorder
Researchers at the National Institutes of Health, led by Dr. Dan Kastner, have led the way in the discovery and understanding of numerous autoinflammatory diseases.
Read Article
Another Biosimilar Approval - Etanercep-szzs by Novartis
Yesterday the U.S. Food and Drug Administration approved a new biosimilar, Erelzi, (etanercept-szzs), for the same multipile indications as the originator Enbrel, including rheumatoid arthritis, plaque psoriasis, Erelzi, will be generically labelled as etanercept-szzs.
Read Article
HMGB1 as a Biomarker for Polymyositis and Dermatomyositis
High mobility group box chromosomal protein 1 (HMGB1) is a DNA-binding protein that functions as a structural co-factor. HMGB1 is actively secreted by macrophage/monocytes via inflammatory stimuli and is elaborated during apoptosis.
Read Article
FDA Approves Updated Denosumab Warnings
In 2015, the Food and Drug Administration (FDA) updated the warnings of all marked bisphosphonates to include the risk of osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF).
Read Article
Zurampic Helps Allopurinol Non-Responders
Lesinurad (Zurampic) was approved earlier this year as adjunctive therapy to other urate-lowering therapies. It is a selective uric acid reabsorption inhibitor (URAT-1 inhibitor) designed to treat gout, and be used in combination with other xanthine oxidase inhibitors.
Read Article
RheumNow Week in Review – 26 August 2016
Dr. Jack Cush reviews news and journal reports from the past week on RheumNow.com.
Read Article
Prior Cancer Patients May Safely Receive TNF Inhibitors or Rituximab
Current guidelines regarding the use of biologics in patients who have previously had a malignancy are based more on opinion than evidence.
Read Article
